Revvity Announces Strategic Divestiture and Outlook for 2026
Revvity, Inc. is divesting its China immunodiagnostics business amid ongoing market challenges to focus on the more resilient Life Sciences segment in China. The company reported strong growth driven by increased pharma and biotech spending and anticipates a pro forma organic growth of 3%–4% for 2026.
Tickers: $RVTY
Topics: AI adoption divestiture organic growth outlook pharma spending recovery strategic realignment